Researchers in biotech, academia and Big Pharma are offering puzzle pieces to crack CAR-T for solid tumors. Will they ever snap together?

Researchers in biotech, academia and Big Pharma are offering puzzle pieces to crack CAR-T for solid tumors. Will they ever snap together?

Source: 
Endpoints
snippet: 

The idea seemed promising enough.

By the time a group of scientists reported an attempt to treat colon cancer with engineered T cells drawn from patients, expanded and armed with artificial surface proteins in 2010, the experimental therapy — known as CAR-T, short for chimeric antigen receptor transduced T cells — had turned from an eccentric therapeutic proposal to a somewhat viable approach being tested in the clinic. The target, HER2, was one of the most extensively studied targets in cancer, implicated in cancers of breast, bladder, ovary, pancreas, and more.